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Objectives. This study was conducted to determine possible
age-dependent changes in the responsiveness of human cardiac
muscarinic receptors.
Background. It is well known that the baroreflex activity
decreases with aging. However, the mechanisms underlying this
phenomenon are not completely understood at present.
Methods. In six healthy young (mean [6SEM] age 26 6 2
years) and six healthy older volunteers (mean age 60 6 2 years),
we determined 1) the effects of graded doses of atropine (bolus
application, six doses, each for 20 min, range 0.03 to 0.96 mg) and
the M1-cholinoceptor selective antagonist pirenzepine (bolus ap-
plication, eight doses, each for 20 min, range 0.04 to 10 mg) on
heart rate, blood pressure and systolic time intervals (as measure
of inotropism); and 2) the baroreflex activity by assessing the
bradycardic response to phenylephrine.
Results. Atropine and pirenzepine caused biphasic effects on
heart rate: At lower doses (<0.12 mg for atropine, <5 mg for
pirenzepine) they decreased heart rate, whereas at higher doses
they increased heart rate. Heart rate decreases induced by both
antimuscarinic drugs were significantly larger in the young vol-
unteers than in the older volunteers, whereas heart rate increases
were not significantly different for both drugs. Atropine and
pirenzepine did not significantly affect blood pressure and systolic
time intervals. Infusion of graded doses of phenylephrine (four
doses ranging from 0.1 to 1.0 mg/kg body weight per min for
15 min each) caused a higher increase in systolic blood pressure
and a smaller decrease in heart rate at each dose in the older
volunteers than in the young volunteers. The slopes of the
regression lines were 16 6 2.3 ms/mm Hg for the young and 6 6
0.5 ms/mm Hg for the older volunteers (p < 0.01).
Conclusions. Human cardiac muscarinic receptor activity is
diminished with increasing age; such decreased cardiac musca-
rinic receptor activity could contribute to the decrease in barore-
flex activity with aging. In contrast, antimuscarinic drugs seem to
have no effect on human cardiac contractility.
(J Am Coll Cardiol 1997;29:187–93)
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Aging is associated with a decrease in baroreflex activity (1,2).
Thus, several groups have shown (3–6) that the reflex bradycardia
to the alpha-adrenoceptor agonist phenylephrine or to angioten-
sin II is reduced in aging. It is generally believed that the decrease
in heart rate (HR) accompanying increases in blood pressure
(BP) is due to activation of parasympathetic outflow to the heart
(7–9). Thus, one possible explanation for a reduced baroreflex
sensitivity could be impairment of cardiac muscarinic receptor
function with aging. It is well known that aging is associated with
a reduced responsiveness of many hormone receptors (10).
Although many studies have been published on age-dependent
changes in human alpha- and beta-adrenergic receptors (1,11)
little is known about age-dependent changes in humanmuscarinic
receptors. For example, it has been demonstrated in isolated
human right atria (12) and left ventricles (13) that beta-
adrenergic receptor responsiveness declines with age, whereas
nothing is known about age-dependent changes in human cardiac
muscarinic receptors. The present study therefore sought to
determine whether human cardiac muscarinic receptors might
undergo age-dependent changes and whether such changes might
contribute to the reduced baroreflex sensitivity associated with
aging. For this purpose we used the findings of Wellstein and
Pitschner (14,15) that atropine and the M1-cholinoceptor selec-
tive antagonist pirenzepine (16) caused biphasic effects on HR in
healthy volunteers: at low doses both antimuscarinic drugs de-
creased HR, whereas at higher doses they increased HR. There-
fore, we studied the effects of graded doses of atropine and
pirenzepine on HR, BP and systolic time intervals (STIs [as a
measure of inotropism] in six young and six older healthy volun-
teers). We also assessed the baroreceptor sensitivity in these
volunteers by determining the bradycardic response to
phenylephrine-induced BP increases.
Methods
Subjects. The study included six young normal healthy
male subjects (22 to 29 years old, mean [6SEM] age 26 6 1)
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and six older healthy volunteers (54 to 67 years old, mean age
60 6 2). No subject was a hospital staff member. At baseline,
systolic and diastolic BP was 112 6 1/76 6 1 mm Hg versus
124 6 4/79 6 1 mm Hg; HR was 62 6 2 versus 60 6 1
beats/min; and body weight was 72.2 versus 64 kg in young and
older volunteers, respectively. Normal health status was previ-
ously established by medical history, physical examination,
biochemical and hematologic screening and electrocardiogram
(ECG). All volunteers had undergone this examination to
exclude asthma, chronic pulmonary disease, diabetes mellitus,
hypertension, cardiac disease and other symptoms pertaining
to the cardiovascular system. They were of average physical
fitness, and they had not taken any medication during the 6
weeks before entry into the study. All had fasted from 11 PM on
the evening before the study. Smoking was prohibited on the
morning of the study.
The experimental procedure and its purpose were thor-
oughly explained to all subjects, and written consent obtained.
The study protocol was approved by the Ethical Committee of
the University of Halle-Wittenberg.
Study protocol. All experiments were carried out in a quiet
air-conditioned room with the volunteers in a supine position.
Subjects were studied on three occasions, with at least 1 week
between each treatment regimen. After arrival at the clinical
laboratory at 7 AM and after placement of the instruments,
indwelling polythene catheters were positioned in an anticubi-
tal vein of each arm. Blood samples were drawn from the left
arm, and drugs were administered in the right arm. After at
least 30 min of rest in supine position, the experiments were
started with incremental doses of atropine, pirenzepine or
phenylephrine.
Examination of muscarinic receptor function. Atropine
sulfate (Atropium Sulfuricum, Eifelfango, Bad Neuenahr,
Germany) and pirenzepine (Gastrozepin, Thomae, Biberach
an der Riss, Germany) were injected over 5 min in increasing
doses of 0.03-, 0.06-, 0.12-, 0.24-, 0.48- and 0.96-mg bolus and
0.04-, 0.08-, 0.16-, 0.32-, 0.64-, 1.25-, 5- and 10-mg bolus over
5 min, respectively, with every dose step requiring 20 min. The
BP was determined six times at minute 5, 10, 15, 16, 17 and 18
of each dose step. The mean value of these six recordings was
chosen for analysis of the dose–response curve. The STIs were
recorded during the last minute of each dose step; thereafter,
blood samples were taken. All measurements were performed
with the subjects in a supine position. The design of this study
was randomized, simple blind and crossover. Only mild side
effects of atropine and pirenzepine, such as dry mouth and
disorientation, were observed.
Examination of baroreceptor sensitivity. Phenylephrine
hydrochloride (Neo-Synephrine hydrochloride, Sanofi) was
infused in graded doses of 0.1, 0.2, 0.5 and 1 mg/kg body weight
per min for 15 min each, as previously described (17). During
the last 5 min of each dose step of the alpha-adrenoceptor
agonist infusion, BP was measured at 1-min intervals, and the
mean value of these five recordings was taken for construction
of the dose–response curve. All measurements were per-
formed with the subjects in a supine position.
Measurements. Systolic and diastolic (phase V) BP was
measured by means of an automatic device (Dinamap, Cri-
tikon). Measurements of STI were obtained noninvasively,
according to standard techniques (18,19), from simultaneous
recordings of an ECG lead, a phonocardiogram (from the third
left intercostal space, filter t) and a carotid pulse tracing at a
high paper speed of 100 mm/s using a 6/12 Elektrocardiograph
BIOSET 8000 (Ho¨rmann Medizintechnik Zwo¨nitz). At each
dose level of the muscarinic receptor antagonists, the STI
recordings were made during quiet respiration after the last BP
measurement. The following intervals were measured: 1) RR
interval (ms) of the ECG, from which HR (beats/min) was
calculated; 2) duration of the electromechanical systole (QS2)
(ms) from beginning of the Q wave of the ECG to the first high
frequency vibrations of the second heart sound; 3) duration of
the left ventricular ejection time (ms) from the rapid upstroke
to the trough of the incisural notch of the carotid pulse tracing;
4) duration of the preejection period (PEP) (ms), derived
mathematically by subtracting left ventricular ejection time
from QS2. At each dose the mean of five cardiac cycles was
taken to describe the dose–response relation. Previous inves-
tigations (20) have demonstrated that averaging five cardiac
cycles is sufficient for an accurate determination of STI, and
increasing the number of beats analyzed to 20 cycles does not
significantly improve the accuracy of the measurements. The
QS2 is highly dependent on changes in HR (18,19,21). There-
fore, in at least 15 volunteers we examined the relation
between an increase in HR induced by incremental intrave-
nous doses of atropine (dose range 0.1 to 2.0 mg) and
shortening of QS2 to correct STIs for alterations in HR, as
recently described (22); QS2 corrected for HR is herein
referred to as QS2c.
The baroreceptor sensitivity was determined as described
by Smyth et al. (23) with slight modification. Briefly, the
baroreceptor sensitivity was calculated by relating the increase
in pulse interval (ms) to the transient increase in systolic BP
(mm Hg) induced by infusion of phenylephrine. Plotting pulse
interval against systolic BP results in a linear relation, and the
slope of this relation is a measure of baroreflex sensitivity (23).
The steeper the slope (i.e., the greater the increase in pulse
interval per mm Hg increase in systolic BP) the greater the
sensitivity of the reflex. The baroreflex sensitivity in both age
groups was assessed by multiple regression analysis with help
of a computer program.
Abbreviations and Acronyms
BP 5 blood pressure
ECG 5 electrocardiogram
QS2 5 electromechanical systole
HR 5 heart rate
QS2c 5 heart rate-corrected electromechanical systole
PEP 5 preejection period
STI 5 systolic time interval
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Analytic methodology. Blood samples for catecholamine
determinations were withdrawn through the indwelling fore-
arm venous catheter into ice-cold EDTA tubes. Samples were
centrifuged at 2000 rpm for 10 min at 48C, and the plasma was
removed and quickly frozen at 2808C. Plasma catecholamine
levels were measured by high performance liquid chromatog-
raphy with fluoremetric detection, as previously described (24).
Data analysis. The Mann-Whitney test was used to com-
pare differences between young and older subjects of the
effects of different doses of pirenzepine and atropine. Within-
study day changes from baseline were tested for significance by
analysis of variance for repeated measures (Friedman non-
parametric repeated measures test); p , 0.05 was considered
to be significant. Results are presented as mean value 6 SEM.
Statistical calculations were performed using the InSTAT
program (GraphPAD Software).
Results
Muscarinic receptor function. Atropine. Figure 1 shows
the effects of atropine on HR in young and older volunteers. In
young subjects atropine caused a significant decrease in HR at
low doses (maximum 214 beats/min at 0.12 mg), whereas in
older subjects atropine only marginally decreased HR at these
doses. In contrast, at higher doses (.0.12 mg), atropine caused
a dose-dependent increase in HR that was not different
between the two groups (p . 0.7). Atropine evoked a slight
increase in systolic and diastolic BP, mainly at doses.0.12 mg,
but this response was not significantly different between the
two groups (Fig. 2). Atropine had no significant effect on STI
variables PEP or QS2c (Table 1).
Pirenzepine. Similar to atropine, the selective M1-cholino-
ceptor antagonist pirenzepine at low doses (up to ;5-mg
bolus) induced a significant reduction in HR in the young
volunteers (maximum 213.5 beats/min at 0.64 mg). In the
older volunteers this response was again markedly blunted. In
contrast, the 10-mg dose of pirenzepine slightly increased HR
in both groups to a similar extent (Fig. 3). Pirenzepine had no
significant influence on diastolic BP in young and older
volunteers, but it slightly increased systolic BP, mainly at
higher doses, and this increase appeared to be more pro-
nounced in the older volunteers (Fig. 4). Similar to atropine,
pirenzepine had no consistent effect on STI variables, PEP and
QS2c (Table 2).
Plasma norepinephrine levels at rest were significantly
higher in the older (238 6 31 pg/ml) than in the young
volunteers (143 6 26 pg/ml, p , 0.05); atropine and pirenz-
epine did not affect plasma catecholamine levels (data not
shown).
Baroreceptor activity. In the older volunteers, each dose of
phenylephrine resulted in a significantly larger increase in
systolic BP and a smaller decrease in HR than in the young
volunteers (Fig. 5). The slopes of the regression line were 166
2.3 ms/mm Hg for the young and 6.0 6 0.5 ms/mm Hg for the
older volunteers (p , 0.01).
Discussion
Effect of pirenzepine and atropine on heart rate. In the
present study, the nonselective muscarinic receptor antagonist
atropine and the M1-cholinoceptor selective antagonist piren-
zepine caused dose-dependent biphasic effects on HR in
healthy volunteers: At low doses they significantly decreased
Figure 1. Effect of atropine on heart rate (HR) in young and older
volunteers. Atropine was intravenously injected in six graded doses
from 0.03- to 0.96-mg bolus each over 5 min. Each dose step took
20 min. Data are mean value 6 SEM of six experiments. *p , 0.05,
older versus young volunteers. bpm 5 beats/minute.
Figure 2. Effect of atropine on diastolic (left) and
systolic (right) blood pressure (BP) in young and older
volunteers. Format as in Figure 1.
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HR, whereas at higher doses they increased HR in accordance
with previously reported data (14,15). It has been postulated
(25) that the decrease in HR is caused by inhibition of
presynaptic inhibitory M1-cholinoceptors, thereby enhancing
the release of acetylcholine. The following findings favor this
hypothesis: 1) The decrease in HR does not appear to be
mediated by central vagal stimulation because at these low
doses, neither pirenzepine nor atropine cross the blood–brain
barrier (25); 2) the decrease in HR is not due to changes in
sympathetic activity because it has been shown (15,25–27) that
propranolol does not affect the HR-reducing effects of piren-
zepine and atropine; 3) it has been shown (25,28,29) in heart
transplant recipients that the HR-reducing effect of pirenz-
epine and atropine can be observed only in the native (inner-
vated) but not in the transplanted (denervated) right atrium.
Taken together, the most plausible explanation for the de-
crease in HR induced by low doses of pirenzepine and atropine
is inhibition of presynaptic M1-cholinoceptors, thereby en-
hancing the release of acetylcholine, which activates postsyn-
aptic in the human heart predominantly M2-cholinoceptors
(30,31), thus decreasing HR. In favor of the involvement of
M1-cholinoceptors is the finding that the decrease in HR
induced by the M1-cholinoceptor selective antagonist pirenz-
epine covered a much larger dose range than that of the
nonselective antagonist atropine.
Negative chronotropic effect of atropine and pirenzepine in
older volunteers. The main finding of the present study was
that the reduction in HR induced by low doses of pirenzepine
and atropine was significantly attenuated in the group of older
volunteers. In contrast, the HR-accelerating effects of higher
doses of atropine and pirenzepine seem not to be different
between the young and older volunteers. As discussed earlier,
the HR-reducing effect of the two antimuscarinic drugs is very
likely due to activation of presynaptic M1-cholinoceptors,
whereas the well known HR-increasing effect is mediated by
blockade of cardiac M2-cholinoceptors, thereby withdrawing
vagal tone. Accordingly, the present results showing significant
differences in HR reduction between young and older volun-
teers favor the idea that 1) either with increasing age, inhibi-
tion of presynaptic M1-cholinoceptors leads to a diminished
release of acetylcholine, or 2) that with increasing age, the
function of postsynaptic M2-cholinoceptors mediating brady-
cardia is decreased. We favor the latter possibility because it
has been shown in rat heart (32) that with advanced age,
activity of acetylcholine esterase declines, that is, it could be
speculated that the concentration of acetylcholine reaching the
postsynaptic M2-cholinoceptor increases rather than decreases
with age. However, experimental proof of this hypothesis is
lacking at present. Nevertheless, independent of whether the
activity of M1- or M2-cholinoceptors is decreased, such a
reduction will finally lead to a decrease in vagal responsiveness
with advanced age.
Baroreceptor sensitivity and aging. A vast body of evi-
dence has accumulated that supports the finding that with
increasing age, the sensitivity of the baroreflex declines
(1,2,11). The present results are in accordance with these
findings: They clearly show that the bradycardic effect accom-
panying phenylephrine-induced increases in BP at each dose
was smaller in the older than in the younger volunteers. It is
generally believed that this decrease in HR is due to activation
of parasympathetic outflow to the heart by the increase in BP
(7–9). As the present results show, activity of the muscarinic
Figure 3. Effect of pirenzepine on heart rate (HR) in young and older
volunteers. Pirenzepine was intravenously injected in eight incremen-
tal doses from 0.04- to 10.0-mg bolus each over 5 min. Each dose step
took 20 min. Data are mean value 6 SEM of six experiments. *p ,
0.05, older versus young volunteers.
Table 1. Effect of Atropine on Variables of Systolic Time Interval in Young and Older Volunteers*
Dose of Atropine (mg bolus)
0.03 0.06 0.12 0.24 0.48 0.96
DQS2c
Young group 1.46 2.2 4.1 6 3.0 7.7 6 3.8 3.5 6 4.2 22.6 6 4.3 25.7 6 3.4
Older group 5.96 2.7 7.6 6 4.4 9.0 6 4.2 6.7 6 4.9 0.74 6 3.5 1.3 6 2.7
DPEP
Young group 21.4 6 1.8 2.4 6 1.5 5.3 6 2.1 3.6 6 2.1 0.8 6 3.2 3.8 6 4.4
Older group 0.26 2.9 1.3 6 3.5 2.9 6 2.5 21.4 6 3.2 0.2 6 3.4 20.5 6 2.6
*Atropine was intravenously injected in six incremental doses from 0.03- to 0.96-mg bolus each over 5 min; each dose
step took 20 min. Systolic time intervals were recorded during each dose step 19 min after bolus application of atropine.
Data presented are mean value 6 SEM of six experiments. DPEP 5 changes in preejection period; DQS2c 5 changes in
heart rate-corrected electromechanical systole.
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receptors in the human heart is diminished with aging. Thus, it
is tempting to speculate that this reduced activity of muscarinic
receptors might contribute to the reduction in baroreceptor
sensitivity with aging: With reduced muscarinic receptor activ-
ity, a given level of activation of parasympathetic outflow to the
heart should result in a smaller negative chronotropic effect.
Effect of atropine and pirenzepine on BP and STI. In
contrast at higher (nonselective) doses, pirenzepine and atro-
pine increased HR, but this increase was not significantly
different between the young and older volunteers. The HR-
increasing effect of antimuscarinic drugs is very likely due to
withdrawal of vagal tone, thereby preventing vagal inhibition of
sympathetic activity. Thus, the finding that the increase in HR
is not different between young and older volunteers could
indicate that sympathetic activity might be not significantly
different between the two groups. However, plasma norepi-
nephrine levels were significantly higher in the older than in
the young volunteers (see Results), in accordance with previ-
ous findings (33). Such an increase in plasma norepinephrine
levels, together with microneuronal recordings from sympa-
thetic nerves to skeletal muscle (34–36) has led to the concept
that with increasing age, sympathetic activity increases. There-
fore, the finding that after withdrawal of vagal activity by
higher doses of atropine and pirenzepine, higher norepineph-
rine levels (and higher sympathetic activity) in the older
volunteers caused the same increase in HR as did lower levels
in the young volunteers favors the idea that cardiac beta-
adrenergic receptors might be desensitized with aging. Two
recent studies support this idea: It has been shown in human
right atria (12) as well as in human left ventricles (13) that
beta-adrenergic receptor responsiveness declines with aging.
However, such subsensitivity of cardiac beta-adrenergic recep-
tors might be masked by the finding that baroreflex control of
the heart is reduced in older subjects (Fig. 5). In fact, White
and Leenen (37) recently showed that isoprenaline infusion in
young and old subjects caused nearly identical increases in HR;
however, after ganglionic blockade with trimetaphane, thereby
inhibiting baroreflex activity, isoprenaline caused a markedly
higher increase in HR in the young volunteers than it did in
older volunteers, thus supporting the concept of a decrease in
beta-adrenergic receptor responsiveness with aging.
Evidence has accumulated that human ventricular myocar-
dium contains M2-cholinoceptors that couple by means of Gi
to inhibition of adenylyl cyclase (30,31,38). Several studies
have shown that after beta-adrenergic stimulation, activation
of these receptors by muscarinic agonists can reduce contrac-
tile force in vitro on isolated electrically driven left ventricular
preparations (31,38) as well as in vivo (39). However, in the
absence of beta-adrenergic stimulation, muscarinic agonists
were inactive; similarly, atropine in vivo did not affect beta-
adrenergic increases in contractile force (39), indicating that
physiologically relevant vagal inhibition of beta-adrenergic
control of cardiac contractility does not exist in humans.
The lack of effect of atropine despite the existence of M2-
Figure 4. Effect of pirenzepine on diastolic (left) and
systolic (right) blood pressure (BP) in young and older
volunteers. Format as in Figure 3.
Table 2. Effect of Pirenzepine on Variables of Systolic Time Interval in Young and Older Volunteers*
Dose of Pirenzepine (mg bolus)
0.04 0.08 0.16 0.32 0.64 1.25 5 10
DQS2c
Young group 3.56 0.8 7.1 6 0.7 8.7 6 0.9 9.1 6 1.2 8.6 6 1.0 8.0 6 1.4 5.0 6 2.3 4.2 6 2.2
Older group 3.46 2.0 4.3 6 3.0 2.7 6 3.8 8.7 6 5.0 9.9 6 4.9 5.4 6 6.2 3.7 6 5.0 3.1 6 4.7
DPEP
Young group 5.26 2.1 7.1 6 2.2 8.0 6 1.7 7.6 6 2.2 9.1 6 1.8 6.1 6 2.4 3.9 6 3.0 5.0 6 2.0
Older group 20.5 6 1.4 0.7 6 2.7 20.2 6 3.1 1.6 6 1.5 2.0 6 2.7 2.0 6 2.7 2.9 6 2.0 1.1 6 3.0
*Pirenzepine was intravenously injected in eight incremental doses from 0.04- to 10-mg bolus each over 5 min. Each dose step took 20 min. Data presented are
mean value 6 SEM of six experiments. Systolic time intervals were recorded during each dose step 19 min after bolus application of pirenzepine. Abbreviations as in
Table 1.
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cholinoceptors may possibly be due to the spare parasympa-
thetic innervation of the human ventricle (40). The present
results are in agreement with these observations because
neither atropine nor pirenzepine considerably affected the STI
variables PEP and QS2c. In this context, it should be noted that
de Mey et al. (41) recently showed that assessment of STI is the
most sensitive noninvasive method for detecting positive and
negative inotropic effects and is certainly more sensitive than
assessment of changes in HR. Therefore, we are certain that
we would have detected positive inotropic effects of atropine or
pirenzepine had they occurred.
It is believed that the impact of parasympathetic activity on
BP control at rest is relatively small (28). In accordance with
this hypothesis, BP changes after pirenzepine and atropine
were not consistent, and no marked differences between young
and older subjects were observed. Nevertheless, the small
changes in systolic BP for both atropine and pirenzepine
followed a pattern similar to that seen for HR: At low doses,
systolic BP showed a tendency to decrease (in the young
volunteers only), whereas at high doses it tended to increase,
and that tendency was similar in both groups. The exact
mechanism underlying these effects will be investigated in a
separate study.
Conclusions. The activity of human muscarinic receptors is
diminished with increasing age; such decreased cardiac mus-
carinic receptor activity could contribute to the decrease in
baroreflex with aging. In contrast, antimuscarinic drugs do not
seem to have any effect on human cardiac contractility.
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